Glucosyl-Hesperidin (CITRAPEAK) for Exercise Performance and Recovery
This study is looking at how different doses of a dietary supplement called glucosyl-hesperidin (CITRAPEAK) affect exercise performance, recovery, blood flow, and thinking skills in healthy, active adults. Researchers want to see if taking 200 mg or 400 mg of CITRAPEAK daily for 8 weeks can improve things like your peak oxygen use (VO2), which shows how well your body uses oxygen during exercise, and your anaerobic power during short, intense bursts of activity. The study aims to enroll about 60 participants between 18 and 50 years old who have a body mass index (BMI) between 25.0 and 30.0 kg/m2. The study's current status is unclear, so it's not known if they are actively recruiting.
- Study design
- This is a randomized, double-blind, placebo-controlled study involving about 60 healthy, recreationally active adults. Participants will be assigned to one of three groups: placebo, 200mg CITRAPEAK, or 400mg CITRAPEAK.
- What's involved
- You would take a daily supplement for 8 weeks and attend multiple visits for assessments, including exercise performance tests, blood flow analysis, and cognitive evaluations.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary measurements for exercise performance are taken at Baseline and Week 8, indicating a follow-up period of at least 8 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
At a glance
Conditions
NCT06672952
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Lindenwood University
Saint Charles, Missouristudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Chad M Kerksick, PhD · PRINCIPAL_INVESTIGATOR · Lindenwood University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from Baseline in Peak VO2 at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) SupplementationBaseline and Week 8
Peak VO2 will be measured as an indicator of maximal aerobic capacity. Higher values reflect improved cardiovascular performance.
- Change from Baseline in Wingate Anaerobic Test Peak Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) SupplementationBaseline and Week 8
Peak anaerobic power will be measured to assess maximal power output during high-intensity exercise. Higher values indicate improved anaerobic performance.
- Change from Baseline in Wingate Anaerobic Test Mean Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) SupplementationBaseline and Week 8
Wingate Anaerobic Test Mean anaerobic power will be recorded during repeated high-intensity exercise, with higher values indicating enhanced anaerobic endurance.
- Change from Baseline in Fatigue Rate at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) SupplementationBaseline and Week 8
Wingate Anaerobic Test Fatigue rate will be measured as the decline in power over time during anaerobic exercise, with a lower rate indicating improved endurance.
- Change from Baseline in Perceived Indicators of Recovery, Training Readiness, Soreness, and Overall Feel Using Visual Analog Scales (VAS) at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) SupplementationBaseline and Week 8
Perceived recovery, training readiness, soreness, recovery, and general "feel" will be self-rated using visual analog scales (VAS), with higher values indicating greater perceived improvements in each category.
- Change from Baseline in Brachial Artery Blood Flow Measured 0, 30, and 60 Minutes After Acute and Prolonged Ingestion of Glucosyl-Hesperidin (CITRAPEAK)Baseline and Week 8, measured at 0, 30, and 60 minutes post-ingestion.
Brachial artery blood flow will be measured to assess vascular response to CITRAPEAK at baseline and after 8 weeks of supplementation, with measurements taken at 0, 30, and 60 minutes post-ingestion.